This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Efficacy and Safety of Topiramate Monotherapy in Civilian Posttraumatic Stress Disorder: A Randomized, Double-Blind, Placebo-Controlled Study

Phebe Tucker, MD; Richard P. Trautman, MD; Dorothy B. Wyatt, RN; Jamie Thompson; Shu-Chen Wu, PhD; Julie A. Capece, BA; and Norman R. Rosenthal, MD

Published: February 15, 2007

Article Abstract

Objective: This double-blind, placebo-controlled trial assessed efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder (PTSD).

Method: Outpatients (18-64 years) with DSM-IV non-combat-related PTSD and Clinician-Administered PTSD Scale (CAPS) scores >= 50 were eligible. Topiramate was started at 25 mg/day and titrated by 25-50 mg/week to 400 mg/day or maximum tolerated dose. Data were collected between April 26, 2002, and February 4, 2004. Primary efficacy, change in total CAPS score, and secondary efficacy measures were assessed by analysis of covariance in the intent-to-treat (ITT) population with last observation carried forward.

Results: The ITT population comprised 38 patients with mean ± SD baseline total CAPS scores of 88.3 ± 13.8 (topiramate, N = 19) and 91.1 ± 13.7 (placebo, N = 19). Although a decrease in total CAPS score was noted (topiramate, -52.7; placebo, -42.0), this difference was not statistically significant (p = .232). Topiramate-treated patients exhibited significant reductions in reexperiencing symptoms (CAPS cluster B: topiramate, 74.9%; placebo, 50.2%; p = .038) and Treatment Outcome PTSD scale (topiramate, 68.0%; placebo, 41.6%; p = .025). Reductions approaching statistical significance, based on a nominal p value, were noted in mean total Clinical Global Impressions-Improvement Scale scores (topiramate, 1.9 ± 1.2; placebo, 2.6 ± 1.1; p = .055).

Conclusion: These preliminary results suggest that further, adequately powered studies of topiramate for the treatment of civilian PTSD are warranted.

Volume: 68

Quick Links: PTSD , Trauma

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...